

Munchmeyer's Disease – A case report

Akhilanand Chaurasia^{1,*}, Vaibhav Mishra², Gaurav Katheriya³

¹Assistant Professor, ^{2,3}Resident, Dept. of Oral Medicine & Radiology, Faculty of Dental Sciences, King George's Medical University, Lucknow

***Corresponding Author:**

Email: chaurasiaakhilanand49@gmail.com

Abstract

Fibrodysplasia ossificans progressive (FOP) is a rare autosomal dominant disease. It is also known as Myositis ossificans progressiva, Stone man disease or Munchmeyer's disease. Herein a rare case of Fibrodysplasia ossificans progressive is presented.

Keywords: Fibrodysplasia ossificans progressive, Myositis ossificans, Soft tissue ossifications

Access this article online

Website:

www.innovativepublication.com

DOI:

10.5958/2395-6194.2016.00034.5

Introduction

Fibrodysplasia ossificans progressive (FOP) is a rare autosomal dominant¹⁻³ disease. It is also known as Myositis ossificans progressiva, Stone man disease or Munchmeyer's disease⁴. It is characterized by widespread soft tissue ossification and congenital stigmata of the extremities affecting all ethnic backgrounds⁵. It was first described by Patin⁶. The term fibrodysplasia ossificans progressive (FOP) is preferred to myositis ossificans because ectopic osteogenesis occurs in the connective tissue within muscles, fasciae, ligaments, tendons and joint capsules rather than in the muscle fibers themselves⁴. The worldwide reported prevalence is approximately 1/2,000,000. However there is no ethnic, racial, gender or geographic predilection to Fibrodysplasia ossificans progressive⁷. The most common age for FOP occurrence is usually between birth and 10 years with a mean age of three years. Children who have FOP appear normal at birth except for congenital malformations of the great toes. It is pathologically characterized by progressive replacement of muscles, tendons, ligaments, fascia and aponeurosis by bone leading to progressive stiffness of the adjacent joints and particularly the chest wall leading to pneumonia and death. Histological examination of early FOP lesions reveals an intense perivascular lymphocytic infiltrate followed by lymphocyte associated death of skeletal muscle and robust development of fibro proliferative tissue with extensive neovascularity and mast cell infiltration. Tissues from FOP lesions at later stages of maturation exhibit characteristic features of endochondral ossification that support ectopic hematopoiesis⁸. It is

particularly disabling in children and is characterized by two cardinal features heterotopic progressive osteogenesis and congenital abnormalities of the great toes^{4,9}. The most characteristic deformity is microdactyly of both halluces due to a single phalanx in valgus position^{10,11}. Individuals with Fibrodysplasia ossificans progressive are normal at birth except for having valgus deformity of great toes. Heterotopic ossification is heralded by the rapid appearance of large painful swellings of highly vascular fibro-proliferative tissue involving tendons, ligaments, fascia, and skeletal muscle. These pre-osseous swellings progress along a pathway of endochondral ossification to form mature heterotopic bone¹². Heterotopic ossification in FOP progresses in specific anatomic and temporal patterns. During the first decade of life, sporadic episodes of painful soft tissue swellings (flare-ups) occur which are commonly mistaken for tumors¹³. These are often precipitated by soft tissue injury, intramuscular injections, viral infection, muscular stretching, falls or fatigue. These flare-ups transform skeletal muscles, tendons, ligaments, fascia, and aponeuroses through an endochondral process into ribbons, sheets and plates of heterotopic bone that span the joints and lock them in place and render movement impossible^{14,15}. The early clinical status of FOP is characterized by soft tissue ossification involving neck primarily followed by lower limbs and dorsum¹⁶. The disease is characterized by frequent edemas as a result of inflammatory processes that cause ossification and subsequently restriction of motility of the affected region. Congenital abnormalities usually associated with short and/or stiff great toes include short thumbs, fifth finger clinodactyly, short broad femoral neck, exostoses of proximal tibiae and abnormal cervical vertebrae with small bodies, large pedicles and large spinous processes. Spine and shoulder stiffness develops by 10 years and restricted hip movements develop by 20 years. The patients affected by FOP are usually confined to bed by the age of 30 years. FOP S primarily involves neck (50%), dorsal paraspinous region (30%),

head (10%) or limbs (10%). 70% of FOP patients develop temporomandibular joint ankylosis which used to lead to death by starvation¹⁷. Other common sites of ossification include joint capsules, ligaments and plantar fascia. However connective tissue of facial and extraocular muscles, intestines, tongue, larynx and skin are not affected. Involvement of dorsal, axial, cranial and proximal anatomic locations precede involvement of ventral, appendicular, caudal and distal areas of the body¹⁸. Ectopic ossification is hallmark of FOP which occurs during lifespan of a patient, most commonly at mean age of 3 to 5 years^{14,17}. Ectopic ossification follows a well-defined pattern, the axial body being compromised first and most. Shoulder and hip regions are affected more than distal segments of the limbs. Deafness and baldness have been reported in up to one fourth of the cases while mental retardation is rare¹⁷. The other characteristic clinical feature of FOP is acute or chronic limb swelling which is defined as an enlargement of the limb circumference at one or more locations with multifactorial increased tissue turgor¹⁹. Conductive deafness occurs in 50% of patients having FOP^{20,21}. Although the rate of disease progression is variable, most patients are confined to a wheel- chair by their early twenties. Patients with FOP usually succumb later in adulthood at mean age of 40 years to cardiopulmonary complications secondary to thoracic insufficiency syndrome and severe restrictive pulmonary disease due to ossification and ankylosis of the joints of thoracic cage^{22,23}. Recently, FOP has been considered a connective tissue disorder due to over expression of a bone morphogenetic protein, BMP4^{24,25}. However most studies have concluded that dysregulation in bone morphogenetic protein (BMP) signaling is responsible in the pathogenesis of FOP. A single common heterozygous mutation (617G>A; R206H) has been identified in the cytoplasmic domain of activin receptor IA/activin-like kinase 2 (ACVR1/ALK2), a BMP type I receptor²⁶. Exacerbation of FOP may occur spontaneously or can be precipitated by trauma, intramuscular injections including vaccines¹⁹, local anesthesia, especially truncular block near the temporomandibular joint¹⁷, muscle biopsy and careless venepunctur⁴. Trauma is the most important exacerbating factor¹⁷. The differential diagnosis of FOP include Albright hereditary osteodystrophy, pseudomalignant heterotopic ossification, progressive osseous heteroplasia and osteosarcoma.

Case Report

A 10 year old female patient (**Fig. 1**) reported to the outpatient Department of Oral medicine and Radiology with a chief complaint of progressive inability to open mouth since past 1 year. The patient also complained of multiple swellings on the back and right scapular area (**Fig. 2 & Fig. 3**). Multiple bony hard swellings are also noted in posterior occipital

area(**Fig. 4**). On whole body examination, she had laterally deviated short first toes of both feet (**Fig. 5**). Firm round subcutaneous swellings were present on vertebral region, right scapula and right occipital region of the skull. There was marked restriction of movements of the right shoulder and right temporomandibular joint. The patient had no difficulty in neck rotation, sitting and walking. Bilateral temporomandibular joint has decreased mobility on palpation. After a through history it was revealed that swellings had been appearing and subsiding since the patient was 6 years old. On palpation all the swellings appeared firm, non-tender with normal overlying skin. Multiple aspirations of the swelling had been done previously with negative results. Hemogram, erythrocyte sedimentation rate, serum calcium, alkaline phosphatase, creatine phosphokinase, alanine and aspartate transaminases, routine urinalysis, and creatinine clearance were within normal limits. An orthopantogram and whole body radiographic examination was advised. Panoramic radiograph shows decreased right temporomandibular joint space with enlarged maxillary tuberosity. Multiple retained deciduous teeth are also noted in maxilla and mandible(**Fig. 6**). Chest posteroanterior (PA) view including abdomen and arms shows extensive focal and cord-like ossification of muscles and soft tissue of back, chest, abdomen and visualised right arm giving pattern of branching tree(**Fig. 7**). AP radiograph of feet showed microdactyly of the great toes and bilateral hallux valgus(**Fig. 8**). Lateral view of thorax and abdomen shows cord-like ossifications of muscles of back(**Fig. 9**). Axial CT image of thorax shows ossification of back and chest muscles(**Fig. 10a, 10b, 10c**). The 3D CT shows posterior view of trunk and neck exhibiting excellent demonstration of soft tissue and muscle ossifications mimicking tree branching pattern(**Fig. 11**). On the basis of clinical and radiographic features, the resent case is diagnosed as Fibrodysplasia ossificans progressive. Parents were advised to make child avoid sporty games, IM injections, arterial puncture and physiotherapy and avoid any surgery to prevent such episodes.



Fig. 1: Patient photograph



Fig. 4: Photograph of Head showing multiple bony hard swellings in posterior occipital area



Fig. 2



Fig. 5: Photograph of feet showing laterally deviated short first toes of both feet



Fig. 3

Fig. 2 & 3: Photograph of back showing multiple swellings on the back and right scapular area



Fig. 6: Panoramic radiograph showing decreased right temporomandibular joint space with enlarged maxillary tuberosity. Multiple retained deciduous teeth are also noted in maxilla and mandible



Fig. 7: Chest posteroanterior (PA) view including abdomen and arms showing extensive focal and cord-like ossification of muscles and soft tissue of back, chest, abdomen and visualized right arm giving pattern of branching tree



Fig. 9: Lateral view of thorax and abdomen showing cord-like ossifications of muscles of back



Fig. 8: AP radiograph of feet showing microdactyly of the great toes and bilateral hallux valgus



Fig. 10 a



Fig. 10 b



Fig. 10 c

Fig. 10a, 10b, 10c: Axial CT images of thorax showing ossification of back and chest muscles



Fig. 11: The 3D CT shows posterior view of trunk and neck exhibiting excellent demonstration of soft tissue and muscle ossifications mimicking tree branching pattern

Discussion

Based upon history and clinic-radiological findings, FOP should be diagnosed as early as possible and noninvasively. The hallmark of diagnosis of FOP is bilateral great toe anomaly present from birth. The bilateral great toe is reported in 79% to 100% of patients having FOP^{17,27,28,29}. Early and correct diagnosis of MOP is fundamental for indication of proper management of the disease. The classical clinical presentation of FOP is highly suggestive and it can allow for diagnosis without unnecessary biopsy and surgical procedures and intra-muscle and intravenous injections which can deteriorate prognosis for the disease. Radiologically Myositis Ossificans Progressiva can be identified approximately two to four weeks after the onset of the process. The calcifications

in FO starts on the extremities and progresses towards the center. This characteristic differentiates MOP from osteosarcoma. In MOP, Computed tomography can be used to delineate the central radiolucency encompassed by peripheral density³⁰. Routine laboratory tests including serum calcium and serum phosphorus are usually normal or non-contributory in FOP. Roentgenograms may aid in documenting minor osseous dysmorphism. Bone scintigraphy with ^{99m}Tc-MDP demonstrates early heterotopic ossification and aid in the assessment of the extent and progression of the FOP. Intramuscular vaccines such as diphtheria-pertussis tetanus, measles, hepatitis B and other injectables can be applied subcutaneously³¹. Dental treatment should be carried out with utmost care peculiarly avoiding anesthesia in the mandible in order to prevent temporomandibular joint ankylosis¹⁷. Prophylaxis of dental cavities is essential to avoid need for more aggressive procedures. The diaphragm, tongue, and extra-ocular muscles are spared from HO. Cardiac muscle and smooth muscle is also spared in FOP. Neck stiffness is an early finding and can precede the appearance of HO at that site. Cervical spine abnormalities include large posterior elements, tall narrow vertebral bodies, and fusion of the facet joints between C2 and C7³². The cervical spine often becomes ankylosed early in life. Other skeletal features associated with FOP are short malformed thumbs, clinodactyly, short broad femoral necks, and proximal medial tibial osteochondromas^{33,34,35}. In addition to progressive immobility, other life-threatening complications include severe weight loss following ankylosis of the jaw, as well as pneumonia and right-sided heart failure resulting from thoracic insufficiency syndrome (TIS)³⁶. Since curative therapy is not available, management is based on the principle of *primum non nocere*, particularly at preventing abnormal ossification. Biopsy of calcified nodules is to be avoided if the diagnosis of FOP is clear on clinical and radiological grounds which may result in recurrent ossification of the site, sometimes worse than the original lesion³⁷. So far no effective treatment for FOP is known. All management is conservative that is, of avoiding conditions potentially provocative of abnormal ossification. Several types of treatment have been tried such as administration of calcium chelators such as sodium etidronate. In acute flare ups, oral corticosteroids and intravenous etidronate can be used simultaneously. Early diagnosis and high index of suspicion will not only prevent the itrogenic harm but may also slow the disease progress and avoid rapid and early deterioration in patient's quality of life³⁸. Misdiagnosis may lead to inadvertent managements like manipulations, biopsies and surgery. Kitterman et al reported incidence of misdiagnosis to be >90%, with 68% receiving inappropriate treatment which lead to permanent disability in about 50% of cases³⁹. Corticosteroids are indicated as first-line treatment at

beginning of flare-ups. A brief 4 day course of high-dose corticosteroids, started within the first 24 hours of a flare-up, may help reduce the intense inflammation and tissue edema seen in the early stages of the disease. The use of corticosteroids should be restricted to treatment of flare-ups that affect major joints, the jaw, or the submandibular area. A typical dose of prednisone is 2 mg/kg/d, administered as a single daily dose. When prednisone is discontinued, a non-steroidal anti-inflammatory drug (NSAID) or cox-2 inhibitor (in conjunction with a leukotriene inhibitor) may be used symptomatically for the duration of the flare-up. Palhares⁴⁰ observed that high doses of ascorbic acid controlled progression of the disease. Decrease in ossifications during the inflammatory process has been attributed to the action of ascorbic acid on modulating synthesis of procollagen type III. In cases of severe MOP with restriction of movements and gastric intolerance, the use of intravenous diphosphonate can be indicated and present good results, as reported by Alpigiani et al⁴¹. The median lifespan is approximately 40 years of age. Most patients are wheelchair-bound by the end of the second decade of life and commonly die of complications of thoracic insufficiency syndrome⁴².

References

- Connor JM, Skirton H, Lunt PW. A three generation family with fibrodysplasia ossificans progressiva. *J Med Genet* 1993;30:687-689.
- Kaplan FS, McCluskey W, Hahn G, Tabas JA, Muenke M, Zasloff MA. Genetic transmission of fibrodysplasia ossificans progressiva: report of a family. *J Bone Joint Surg* 1993;75A:1214-1220.
- Janoff HB, Tabas JA, Shore EM, et al. Mild expression of fibrodysplasia ossificans progressiva: a report of three cases. *J Rheumatol* 1995;22:976-978.
- Brooke MH. Myositis ossificans progressiva. In Brooke MH. A clinician's view of neuromuscular diseases. 2Ed. Baltimore: Williams & Wilkins, 1986:239-242.
- Delatycki M, Rogers JG. The genetics of fibrodysplasia ossificans progressiva. *Clin Orthop Rel Res* 1998;346:15-18.
- Patin G. Lettres choisies de feu M. Guy Patin. Letter of August 27, 1648, to AF. Cologne P. du Laurens, 1692. Tome 1, vol. 5, p. 28.
- Shore EM, Feldman GJ, Xu M, Kaplan FS: The genetics of fibrodysplasia ossificans progressiva. *Clin Rev Bone Miner Metab* 2005,3:201-204.
- Shen Q, Little SC, Xu M, Haupt J, Ast C, Katagiri T, Mundlos S, Seemann P, Kaplan FS, Mullins MC, Shore EM. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. *J Clin Invest*. 2009 Nov;119(11):3462-72.
- Buysse G, Silberstein J, Goemans N, Casaer P. Fibrodysplasia ossificans progressiva: still turning into wood after 300 years? *Eur J Pediatr* 1995;154:694-699.
- Rogers JG, Geho WB. Fibrodysplasia ossificans progressiva. A survey of forty-two cases. *J Bone Joint Surg* 1979;61A:909-914.
- Schroeder HW, Zasloff MA. The hand and foot malformations in fibrodysplasia ossificans progressiva. *Johns Hopkins Med J* 1980;147:73-78.
- Rocke DM, Zasloff M, Peeper J, Cohen RB, Kaplan FS: Age-and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. *Clin Orthop Relat Res* 1994,243-248.
- Kitterman JA, Kantanie S, Rocke DM, Kaplan FS: Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. *Pediatrics* 2005,116:e654-e661.
- Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS: The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty four patients. *J Bone Joint Surg Am* 1993,75:215-219.
- Kaplan FS, Glaser DL, Shore EM, Deirmengian GK, Gupta R, Delai P, Morhart P, Smith R, Le Merrer M, Rogers JG, Connor JM, Kitterman JA: The phenotype of fibrodysplasia ossificans progressiva. *Clin Rev Bone Miner Metab* 2005,3:183-188.
- Reinig JW, Hill SC, Fang M, Marini J, Zasloff MA. Fibrodysplasia Ossificans Progressiva: CT Appearance. *Radiology* 1986;159:153-7.
- Connor JM, Evans DAP. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. *J Bone Joint Surgery (Br)* 1982,64:76-83.
- Pignolo RJ, Suda RK, Kaplan FS: The fibrodysplasia ossificans progressive lesion. *Clin Rev Bone Miner Metabol* 2005,3:195-200.
- Moriatis JM, Gannon FH, Shore EM, Bilker W, Zasloff MA, Kaplan FS. Limb swelling in patients who have fibrodysplasia ossificans progressiva. *Clin Orthop Rel Res* 1997;336:247-253.
- Kaplan FS, Shore EM, Pignolo RJ (eds), name of individual consortium member, and The International Clinical Consortium on FOP. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. *Clin Proc Intl Clin Consort FOP* 4:1-100,2011.
- Levy CE, Lash AT, Janoff HB & Kaplan FS. Conductive Hearing Loss in Individuals with Fibrodysplasia Ossificans Progressiva. *Am J Audiol*.1999;8:29-33.
- Frederick S. Kaplan, David L. Glaser, Nader Hebel, and Eileen M. Shore. Heterotopic Ossification, *J Am Acad Orthop Surg* March/April 2004;12:116-125
- Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. *J Bone Joint Surg Am*. 2010 Mar;92(3):686-91.
- Kaplan FS. Editorial comment. *Clin Orthop Rel Res* 1998;346:2-4.
- Shafritz AB, Shore EM, Gannon FH, et al. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. *N Engl J Med* 1996;335:555-561.
- Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, Le Merrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nature Genetics* 2006,38:525-527.
- Rogers JG, Geho WB. Fibrodysplasia ossificans progressiva. A survey of forty-two cases. *J Bone Joint Surg* 1979;61A:909-914.
- Schroeder HW, Zasloff MA. The hand and foot malformations in fibrodysplasia ossificans progressiva. *Johns Hopkins Med J* 1980;147:73-78.

29. Smith R. Fibrodysplasia (myositis) ossificans progressiva: clinical lessons from a rare disease. *Clin Orthop Rel Res* 1998;346:7-14.
30. Bullough P. *Orthopaedic Pathology*. 3rd ed. London: Times Mirror International Publishers Limited;1997.
31. Buysse G, Silberstein J, Goemans N, Casaer P. Fibrodysplasia Ossificans Progressiva: still turning into wood after 300 years? *Eur J Pediatr* 1995;154:694-99.
32. Schaffer AA, Kaplan FS, Tracy MR, O'Brien ML, Dormans JP, Shore EM, Harland RM, Kusumi K: Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome. *Spine* 2005;30:1379-1385.
33. Kaplan FS, Strear CM, Zasloff MA: Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. *Clin Orthop Relat Res* 1994;238-47.
34. Deirmengian GK, Hebela NM, O'Connell M, Glaser DL, Shore EM, Kaplan FS: Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. *J Bone Joint Surg Am* 2008;90:366-374.
35. Kaplan FS, Xu M, Seemann P, Connor M, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillissen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi S-A, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM: Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. *Hum Mutat* 2009;30:379-90.
36. Kaplan FS, Glaser DL: Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. *Clin Rev Bone Miner Metab* 2005;3:213-216.
37. Connor JM, Evans DA. Fibrodysplasia ossificans progressiva: the clinical features and natural history of 34 patients. *J Bone Joint Surg* 1982;64B:76-83.
38. Tran L, Stein N, Miller S. Fibrodysplasia ossificans progressiva: early diagnosis is critical yet challenging. *J Pediatr*. 2010 Nov;157(5):860.e1.
39. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. *Pediatrics*. 2005 Nov;116(5):e654-61.
40. Palhares DB. Myositis Ossificans Progressive. *Calcif Tissue Int* 1997;60:394.
41. Alpigiani MG, Puleo MG, Callegarini I, Di Bella E, Debbia C, Buzzanca C et al. L, acido diclorometilenbifosfonico nella terapia della miosite ossificante progressiva. *Minerva Pediatr* 1996;48:159-63.
42. Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM: Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. *J Bone Joint Surg Am* 2010;92:686-691.